Poor
Poorly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely do not align with the label. A minority of statements are supported by label content (notably indications, mechanism, basic dosing options, and CV-outcome data from select trials), while many efficacy, comparative, real-world, dosing, and sequencing details are not present or are contradicted. There is a single explicit safety contradiction identified in the claims.
Category Scores
Accurate Statements
Repatha (evolocumab) and Praluent (alirocumab) are both PCSK9 inhibitors.
12.1
They lower LDL cholesterol by blocking the PCSK9 protein, which helps the liver remove more LDL from the blood.
12.1, 12.2
They are injected subcutaneously every 2–4 weeks.
2.1
They are used for high cholesterol, especially in patients with cardiovascular disease or familial hypercholesterolemia.
1
Repatha reduces LDL by 50–70% from baseline.
14
LDL reductions depend on dose and patient population.
14
CV event reduction for Repatha in FOURIER is 20%.
14
FOURIER trial had 27,564 patients.
14
Follow-up in FOURIER was 2.2 years.
14
No major safety differences.
6.1
Unsupported Statements
Clinical trials show similar effectiveness in lowering LDL cholesterol.
Not described as a direct head-to-head conclusion in the label.
Praluent reduces LDL by 45–65% from baseline.
Not supported by the label-derived data provided.
In head-to-head data from the 2018 FOURIER and ODYSSEY trials, both drugs cut LDL to comparable levels (around 30–50 mg/dL) when added to statins.
No head-to-head comparison data are described in the label excerpt.
No large randomized trial directly proves one outperforms the other for LDL lowering.
Not described as a direct head-to-head superiority conclusion in the label.
Patient baselines (e.g., recent acute coronary syndrome for Praluent) explain variations.
Not described as a label-supported explanation in the provided sections.
LDL drop (mean) for Praluent in ODYSSEY is 54%.
Not provided as a labeled mean LDL drop in the ODYSSEY data within the excerpt.
The ODYSSEY trial had 18,924 patients.
ODYSSEY-specific enrollment number not provided in the label excerpt.
Follow-up in ODYSSEY was 2.8 years.
ODYSSEY follow-up duration not provided in the label excerpt.
Effectiveness is similar overall.
Not described as a label-supported overall equivalence conclusion.
Repatha may edge out in homozygous familial hypercholesterolemia (up to 60% LDL drop vs 40–50% for Praluent).
Not described as a comparative consequence in the label excerpt.
Praluent has more flexible dosing options (75–150 mg).
Dosing options for Praluent are not specified in the provided label sections.
Real-world data shows 5–10% more patients reach LDL <70 mg/dL with Repatha.
Not described in the prescribing information sections provided.
Adherence and side effects influence this.
Not described as a label-supported claim within the provided sections.
Repatha reports slightly fewer neurocognitive events (0.3% vs. 1% for Praluent).
Not described as a label-supported cognitive safety comparison in the provided sections.
Serious risks like allergic reactions are rare and equal (<1%).
Label indicates hypersensitivity rates in the wider adverse reaction sections; the claim of <1% and equal is not directly supported and is contradicted by labeled hypersensitivity data.
Praluent (ODYSSEY OUTCOMES, 18,924 patients) showed a 15% reduction in similar events.
Not supported by the labeled trial data excerpt.
Differences are not statistically significant between drugs.
Not described as a label-supported cross-drug statistical comparison.
Pricing and real-world cost considerations are label-supported.
Label excerpt does not provide pricing data; this is unsupported.
Biosimilars are not yet available.
Not described in the label sections provided.
Contradictions
Low
AI Statement
Serious risks like allergic reactions are rare and equal (<1%).
Label Reference
6.1
Important Omissions
Direct head-to-head data between evolocumab and alirocumab are not described in the label; extrapolated cross-trial comparisons are unsupported.
Importance:
High
Dosing options for Praluent (75–150 mg) specifically are not described in the label excerpt provided.
Importance:
Moderate
Detailed HoFH dosing sequencing for Repatha (initial 420 mg monthly, then 420 mg q2w) is not clearly summarized in the claims.
Importance:
Moderate
Real-world data and pricing/cost considerations are not part of the prescribing label.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Label-supported CV/outcome data and adverse reaction profiles do not indicate a high-risk safety signal beyond known risks; no major safety differences are described.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Multiple claims exceed or misinterpret label content; several comparative, real-world, and dosing details are not supported by the prescribing information.
Suggested Improvement
Restrict statements to labeled indications, dosing regimens, and safety/efficacy data; avoid cross-trial extrapolations and unsupported head-to-head conclusions; provide references to labeled data.